Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing
Completed
UCB Pharma
Phase 2
2009-09-02
The primary objective of this study is to investigate the effect of romosozumab compared with
placebo on time to radiographic healing of fresh tibial diaphyseal fractures (fractures in
the midsection of the shinbone).
Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing
Completed
Amgen
Phase 2
2009-09-02
The primary objective of this study is to investigate the effect of romosozumab compared with
placebo on time to radiographic healing of fresh tibial diaphyseal fractures (fractures in
the midsection of the shinbone).
Study To Assess FRacTure Healing With SclerosTin Antibody - Hip
Completed
Amgen
Phase 2
2010-06-20
This is an international, multi-center study to determine the efficacy, safety, and
tolerability of romosozumab (AMG 785) in adults with a fresh unilateral hip fracture, status
post surgical fixation.
A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis
Completed
Amgen
Phase 3
2017-01-16
The primary objective is to evaluate the effect of treatment with romosozumab for 6 months
compared with placebo on percent changes in bone mineral density (BMD) at the lumbar spine as
assessed by dual-energy X-ray absorptiometry (DXA) in postmenopausal women with osteoporosis.
A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis
Completed
Amgen
Phase 3
2018-02-06
To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab at 90 mg/mL
administered subcutaneously (SC) once a month (QM) in postmenopausal women with osteoporosis
either by healthcare provider (HCP) administration with prefilled syringe (PFS) or by subject
self-administration with autoinjector/pen (AI/Pen)
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
